Great! Next, complete checkout for full access to NeuroXT
Welcome back! You've successfully signed in.
Success! Your account is fully activated, you now have access to all content.
Success! Your billing info is updated.
Billing info update failed.
About Us
Vision
Vision
"An AI-powered neuroimaging platform redefining precision treatment for Alzheimer’s disease."
Why?
Alzheimer’s treatment has entered a new era yet only a limited number of patients truly benefit from current therapies. There is a growing need for precise and accessible technology that can predict therapeutic effectiveness and maximize patient outcomes.
How?
By analyzing MRI scans, an advanced AI model predicts amyloid and tau burden to identify the golden therapeutic window the optimal stage at which a patient can most benefit from treatment.
What?
An AI software platform that enables biomarker-based diagnosis and treatment suitability prediction using MRI alone eliminating the need for costly PET scans and making advanced Alzheimer’s care accessible to hospitals worldwide.
History
History
2023
May
Selected for Early Startup Package
Raised Pre-A Series investment from Smilegate
Raised Pre-A Series investment from Korea Investment Accelerator
April
Raised Pre-A Series investment from Daily Partners
2022
December
Raised Pre-A Series investment from Kakao Ventures
August
Signed global clinical collaboration with Newcle Science Inc.
July
Established corporate R&D center
Certified as a venture company
Selected for TIPS (Tech Incubator Program for Startup Korea)
June
Raised seed investment from AJU IB and Mirae Ventures
Secured technology transfer agreement for 6 key patents (Korea University Samrak Cooperation Center)
April
NeuroXT Inc. founded
Partnership
AJU IB InvestmentDAYLI PatnersKakao VenturesKorea Investment AcceleratorKorea University Research And Business FoundationLULULABMira VenturesSmilegate Investment
